IBI Ag Secures $6.1 Million in Funding Round Led by Corteva Inc.
IBI Ag has secured $6.1 million in the first tranche of its Series A funding round, led by Corteva through its Corteva Catalyst platform. Other participants include The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, along with a grant from the Israel Innovation Authority.
The company is developing bio-insecticides using single domain antibody technology, adapted from pharmaceutical applications for agricultural use. Their products target both sucking and chewing insects while maintaining a low ecological footprint and minimal impact on non-targeted organisms. The technology focuses initially on high-value crops with plans to expand to row crop solutions.
IBI Ag ha ottenuto 6,1 milioni di dollari nella prima tranche del suo round di finanziamento di Serie A, guidato da Corteva attraverso la sua piattaforma Corteva Catalyst. Altri partecipanti includono The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, insieme a un finanziamento dell'Autorità per l'Innovazione di Israele.
L'azienda sta sviluppando bio-insetticidi utilizzando la tecnologia degli anticorpi a dominio singolo, adattata dalle applicazioni farmaceutiche per l'uso agricolo. I loro prodotti mirano sia agli insetti succhiatori che a quelli masticatori, mantenendo un basso impatto ecologico e un minimo impatto sugli organismi non bersaglio. La tecnologia si concentra inizialmente su colture ad alto valore, con piani per espandersi a soluzioni per colture a fila.
IBI Ag ha asegurado 6,1 millones de dólares en la primera tranche de su ronda de financiamiento Serie A, liderada por Corteva a través de su plataforma Corteva Catalyst. Otros participantes incluyen The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, junto con una subvención de la Autoridad de Innovación de Israel.
La empresa está desarrollando bioinsecticidas utilizando la tecnología de anticuerpos de dominio único, adaptada de aplicaciones farmacéuticas para uso agrícola. Sus productos atacan tanto a los insectos chupadores como a los masticadores, manteniendo una baja huella ecológica y un impacto mínimo en organismos no objetivos. La tecnología se centra inicialmente en cultivos de alto valor, con planes de expandirse a soluciones para cultivos en hileras.
IBI Ag는 Corteva가 Corteva Catalyst 플랫폼을 통해 주도한 시리즈 A 자금 조달의 첫 번째 트랜치에서 610만 달러를 확보했습니다. 다른 참여자에는 The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group이 포함되며, 이스라엘 혁신청의 보조금도 포함됩니다.
이 회사는 농업용으로 제약 응용 분야에서 적응된 단일 도메인 항체 기술을 사용하여 바이오 살충제를 개발하고 있습니다. 그들의 제품은 흡혈 및 씹는 곤충을 대상으로 하며, 낮은 생태 발자국과 비표적 유기체에 대한 최소한의 영향을 유지합니다. 이 기술은 고부가가치 작물에 처음 집중하고 있으며, 이후 줄기 작물 솔루션으로 확장할 계획입니다.
IBI Ag a sécurisé 6,1 millions de dollars lors de la première tranche de sa levée de fonds de Série A, dirigée par Corteva via sa plateforme Corteva Catalyst. D'autres participants incluent The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group, ainsi qu'une subvention de l'Autorité israélienne de l'innovation.
L'entreprise développe des bio-insecticides en utilisant la technologie des anticorps à domaine unique, adaptée des applications pharmaceutiques pour un usage agricole. Leurs produits ciblent à la fois les insectes suceurs et masticateurs tout en maintenant une faible empreinte écologique et un impact minimal sur les organismes non ciblés. La technologie se concentre initialement sur des cultures de haute valeur, avec des plans pour s'étendre aux solutions pour les cultures en rangées.
IBI Ag hat in der ersten Tranche seiner Serie-A-Finanzierungsrunde 6,1 Millionen Dollar gesichert, angeführt von Corteva über die Corteva Catalyst-Plattform. Weitere Teilnehmer sind The Trendlines Group (TRNLY), Iron Nation, Consensus Business Group sowie ein Zuschuss von der Israel Innovation Authority.
Das Unternehmen entwickelt Bioinsektizide mit Hilfe von Einzel-Domänen-Antikörpertechnologie, die von pharmazeutischen Anwendungen für landwirtschaftliche Zwecke adaptiert wurde. Ihre Produkte zielen sowohl auf saugende als auch auf beißende Insekten ab, während sie eine geringe ökologische Fußabdruck und minimale Auswirkungen auf nicht gezielte Organismen aufrechterhalten. Die Technologie konzentriert sich zunächst auf hochpreisige Kulturen, mit Plänen zur Expansion in Lösungen für Reihenpflanzen.
- Secured $6.1M in Series A funding led by major agricultural company Corteva
- Technology targets broad spectrum of insects with minimal environmental impact
- Strategic partnership with Corteva provides validation of technology platform
- Additional funding through Israel Innovation Authority grant
- Products still under development, not yet commercialized
- Initial focus to high-value crops only
This is the first tranche of a Series A Round for IBI Ag's novel bioinsecticide platform.
NES TZIONA,
IBI Ag has developed technology that leverages single domain antibodies, to produce highly effective crop protection solutions with a low ecological footprint. This technology—adapted from pharma and modified to fit the agricultural market—provides novel modes of action and represents a revolutionary new approach for protecting crops from insects. The products under development target a broad spectrum of insects, both sucking and chewing insects with minimal impact on non-targeted organisms. The company is targeting high value crops to start and will follow with row crop solutions.
"We are thrilled to have the support of our existing and new investors, led by Corteva through their Corteva Catalyst platform," said Arnon Heyman, Chief Executive Officer, IBI Ag. "This investment will help us to accelerate the development of our single domain antibody technology, providing farmers with sustainable and effective crop protection solutions. We believe our single domain antibody technology is a game changer for driving agricultural productivity while preserving the environment, and the investment announced today is a significant step towards delivering this innovation to farmers across the globe."
"We see considerable potential for IBI Ag's bioinsecticides to be a smart solution for farmers to tackle devastating insects while minimizing environmental impacts," said Tom Greene, Senior Director at Corteva Inc. and Global Leader for Corteva Catalyst. "Our investment aligns with our continued drive to put cutting-edge innovation into the hands of farmers and reflects our strategic focus on accelerating development of next generation biological and naturally inspired solutions."
About IBI Ag
IBI-Ag is a pioneer in the Agri-biotech industry, committed to developing innovative and sustainable solutions for crop protection. The company's proprietary technology platform, the first of its kind, utilizes nano-bodies—a type of antibody—to create effective, selective, and safe biological insect control solutions. This breakthrough technology has the potential to protect the global food chain by helping farmers protect their crops with a lower ecological footprint and to transform the agricultural industry by offering an environmentally friendly and cost-effective alternative to chemical pesticides. IBI Ag was established by The Trendlines Group together with the founders Amir Ayali PhD and Rony Oren Benaroya PhD, and with the support of the Israel Innovation Authority.
Media Contacts:
IBI Ag: Arnon Heyman, CEO IBI Ag, e-mail: Arnon.heyman@ibi-ag.com
Photo - https://mma.prnewswire.com/media/2619674/IBI_Ag_team.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/ibi-ag-secures-6-1-million-in-funding-round-led-by-corteva-inc-302375928.html
SOURCE IBI Ag
FAQ
How much funding did IBI Ag raise in its Series A round first tranche?
Who led IBI Ag's Series A funding round in February 2025?
What is unique about IBI Ag's bioinsecticide technology?
Which markets will IBI Ag's bioinsecticide products initially target?
What role does Trendlines Group (TRNLY) play in IBI Ag's funding round?
